生物基PHA材料企业完成新一轮融资

Core Viewpoint - Zhuhai MedPHA Biotechnology Co., Ltd. has successfully completed a Series B financing round, which is seen as a recognition of its technological strength and market prospects, as well as a significant step in accelerating its industrialization process [5][28]. Group 1: Financing History - MedPHA completed its angel round financing in March 2021 [3]. - In May 2022, the company raised tens of millions of RMB in Series A financing [3]. - In December 2023, MedPHA completed a Series A+ financing round, raising several tens of millions of RMB, led by Huafa Group's investment platform [3]. Group 2: Company Positioning - The name "MedPHA" combines "Medicine" and "PHA," indicating the company's unique positioning as an innovative enterprise in both pharmaceuticals and PHA materials [6]. - The third-largest shareholder, Lijun Pharmaceutical Group, has been involved since the company's inception, influencing its strategic direction from a genetic level [8]. Group 3: Shareholder Structure - The largest shareholder, Zhuhai Hengqin Baomei Enterprise Management, holds 50.63% of the shares [9]. - Lijun Pharmaceutical Group holds 5.63% of the shares, indicating a long-term strategic partnership [9][10]. - Other notable shareholders include Zhuhai Hengqin Baoli Enterprise Management and Zhuhai Huajin Lingjian Equity Investment [9]. Group 4: Product Lines - MedPHA has three main product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate health-active small molecules [11]. - Industrial-grade PHA is used in biodegradable packaging and has gained recognition from major companies like Walmart and Costco [13]. - Medical-grade PHA is a core differentiated product, with MedPHA being the first global supplier to receive regulatory approvals from the National Medical Products Administration and the FDA [16]. - The beta-hydroxybutyrate product, branded as "Sainao Si," targets brain health and has been launched in Macau and the United States [18]. Group 5: Milestones Achieved - MedPHA has achieved significant milestones in 2025, including medical certification, capacity expansion, and the completion of Series B financing [21][25][28]. - The company successfully passed ISO 13485:2016 certification for its medical device quality management system, a key qualification for entering the medical device industry [21]. - The industrial-grade PHA production capacity has been expanded to over 2,000 tons, and a cleanroom for medical-grade PHA has been established [25].